A control systems analysis of HIV prevention model using impulsive input
暂无分享,去创建一个
Alessandro Astolfi | Hyeygjeon Chang | Claude H. Moog | Pablo S. Rivadeneira | C. Moog | A. Astolfi | P. Rivadeneira | Hyeygjeon Chang | P. Rivadeneira
[1] Hulin Wu,et al. Modeling HIV dynamics and antiviral response with consideration of time-varying drug exposures, adherence and phenotypic sensitivity. , 2003, Mathematical biosciences.
[2] Peter Vickerman,et al. HIV Treatment as Prevention: Models, Data, and Questions—Towards Evidence-Based Decision-Making , 2012, PLoS medicine.
[3] Ryan Zurakowski,et al. A model predictive control based scheduling method for HIV therapy. , 2006, Journal of theoretical biology.
[4] Louis Tong,et al. Limited Knowledge and Use of HIV Post- and Pre-Exposure Prophylaxis Among Gay and Bisexual Men , 2008 .
[5] Claude H. Moog,et al. Impulsive control of single-input nonlinear systems with application to HIV dynamics , 2012, Appl. Math. Comput..
[6] Sabine Yerly,et al. Early and Prolonged Antiretroviral Therapy Is Associated with an HIV-1-Specific T-Cell Profile Comparable to That of Long-Term Non-Progressors , 2011, PloS one.
[7] Alan S. Perelson,et al. Mathematical Analysis of HIV-1 Dynamics in Vivo , 1999, SIAM Rev..
[8] Tao Yang,et al. Impulsive control , 1999, IEEE Trans. Autom. Control..
[9] E Comets,et al. An in vivo Pharmacokinetic/Pharmacodynamic Model for Antiretroviral Combination , 2003, HIV clinical trials.
[10] Lin Shen,et al. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs , 2008, Nature Medicine.
[11] Alessandro Astolfi,et al. A control systems approach to HIV prevention with impulsive control input , 2012, 2012 IEEE 51st IEEE Conference on Decision and Control (CDC).
[12] John T Brooks,et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. , 2012, The New England journal of medicine.
[13] James D. Campbell,et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. , 2012, The New England journal of medicine.
[14] D. Wodarz,et al. Helper-dependent vs. helper-independent CTL responses in HIV infection: implications for drug therapy and resistance. , 2001, Journal of theoretical biology.
[15] David V Glidden,et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. , 2010, The New England journal of medicine.
[16] Kenneth H Mayer,et al. Preexposure Antiretroviral Prophylaxis Attitudes in High-Risk Boston Area Men Who Report Having Sex With Men: Limited Knowledge and Experience but Potential for Increased Utilization After Education , 2009, Journal of acquired immune deficiency syndromes.
[17] C. Moog,et al. Algebraic Methods for Nonlinear Control Systems , 2006 .
[18] B. Adams,et al. Dynamic multidrug therapies for hiv: optimal and sti control approaches. , 2004, Mathematical biosciences and engineering : MBE.
[19] Malcolm Rowland,et al. Clinical pharmacokinetics : concepts and applications , 1989 .
[20] Hulin Wu,et al. Hierarchical Bayesian inference for HIV dynamic differential equation models incorporating multiple treatment factors , 2010, Biometrical journal. Biometrische Zeitschrift.
[21] M. Nowak,et al. Virus dynamics: Mathematical principles of immunology and virology , 2001 .
[22] Hyungbo Shim,et al. A system theoretic study on a treatment of AIDS patient by achieving long-term non-progressor , 2009, Autom..
[23] A. Perelson,et al. Complex patterns of viral load decay under antiretroviral therapy: influence of pharmacokinetics and intracellular delay. , 2004, Journal of theoretical biology.
[24] Lei Wang,et al. Prevention of HIV-1 infection with early antiretroviral therapy. , 2011, The New England journal of medicine.
[25] Antonios Armaou,et al. An extracellular stochastic model of early HIV infection and the formulation of optimal treatment policy , 2008 .
[26] Doug Taylor,et al. Tenofovir Disoproxil Fumarate for Prevention of HIV Infection in Women: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial , 2007, PLoS clinical trials.
[27] Lynn Morris,et al. Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women , 2010, Science.
[28] Wei Zhang,et al. Bioavailability of extended-release nevirapine 400 and 300 mg in HIV-1: a multicenter, open-label study. , 2011, Clinical therapeutics.
[29] M A Nowak,et al. The role of antigen-independent persistence of memory cytotoxic T lymphocytes. , 2000, International immunology.
[30] Alessandro Astolfi,et al. Activation of Immune Response in Disease Dynamics via Controlled Drug Scheduling , 2009, IEEE Transactions on Automation Science and Engineering.
[31] Lin Shen,et al. A Quantitative Basis for Antiretroviral Therapy for HIV-1 Infection , 2012, Nature Medicine.
[32] Shuzhi Sam Ge,et al. Nonlinear control of a dynamic model of HIV-1 , 2005, IEEE Transactions on Biomedical Engineering.
[33] Lin Shen,et al. Dose–response curve slope is a missing dimension in the analysis of HIV-1 drug resistance , 2011, Proceedings of the National Academy of Sciences.
[34] David Back,et al. Tenofovir, Emtricitabine Intracellular and Plasma, and Efavirenz Plasma Concentration Decay Following Drug Intake Cessation: Implications for HIV Treatment and Prevention , 2013, Journal of acquired immune deficiency syndromes.